Skip to main content

Table 3 Relationship between nuclear ADA3 and nuclear c-MYC co-expression combinatorial phenotypic groups with molecular biomarker status within the whole unselected invasive breast cancer series (n = 588 cases)

From: ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC

 

ADA3low C MYClow

N (%)

ADA3high C MYClow

N (%)

ADA3low C MYChigh

N (%)

ADA3high C MYChigh

N (%)

Significance

X 2

P

ER Status

Negative

59 (39.6)

12 (8.1)

56 (37.6)

22 (14.8)

25.800

<0.001

Positive

113 (26.0)

56 (12.9)

121 (27.9)

144 (33.2)

PR Status

Negative

78 (36.0)

25 (10.3)

74 (30.6)

56 (23.1)

12.803

0.005

Positive

79 (23.7)

43 (12.9)

102 (30.5)

110 (32.9)

HER2 Status*

Negative

6 (54.5)

2 (18.2)

1 (9.1)

2 (18.2)

21.743

0.010

Positive

132 (27.0)

55 (11.2)

152 (31.1)

150 (30.7)

Molecular Subtype

Luminal

99 (25.4)

49 (12.6)

110 (28.3)

131 (33.7)

25.405

<0.001

HER2 Positive

34 (40.0)

10 (11.8)

24 (28.2)

17 (20.0)

Triple Negative

38 (36.2)

7 (6.7)

43 (41.0)

17 (16.2)

Ki67 labelling** Index

Low

42 (23.0)

27 (14.8)

40 (21.9)

74 (40.4)

22.081

<0.001

High

83 (29.9)

30 (10.8)

101 (36.3)

64 (23.0)

p27

Low

114 (38.8)

33(11.2)

89 (30.3)

58 (19.7)

38.276

<0.001

High

40 (16.7)

33 (13.8)

77(32.1)

90 (37.5)

  1. *HER2 Status was assessed using American Society of Clinical Oncology/College of American Pathologists Guidelines Recommendations for HER2 Testing in Breast Cancer and Equivocal (2+) HER2+ cases were confirmed by FISH/CISH. ** Ki67 labelling index dichotomized at 14% according to St Galen consensus guidelines 2013
  2. Analysis within the whole unselected invasive breast cancer series with respect to receptor status, molecular subtype, Ki67 labeling index, and p27 demonstrated a statistically significant correlation across the four groups